Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research for immunotherapy of glioblastoma with autologous heat shock protein gp96

Next Previous
Search
Trial Profile

Research for immunotherapy of glioblastoma with autologous heat shock protein gp96

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HSP Gp96 vaccine Cure and Sure Biotech (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cure&Sure Biotech

    • Most Recent Events

    • 10 Dec 2015 Planned End Date changed from 1 Jun 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov.
    • 10 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Jul 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top